The creator's claims about tesamorelin's role in the GH-IGF-1 axis are scientifically supported. Tesamorelin is confirmed as a GHRH receptor agonist (Claim 1), with human clinical trial evidence demonstrating GHRH's effect on pituitary GH secretion (Claim 2). While Claims 3–4 lack specific evidence in the provided search results, they represent established endocrinological principles. Claim 5 (IGF-1 and muscle growth) is supported by human trial context and PeptIQ's reference literature. Claim 6 appropriately distinguishes tesamorelin as an indirect, step-one signaling molecule rather than a direct muscle builder—a mechanistically accurate and important clarification. The unverified 'Adrian et al., 2019' citation warrants correction, but the underlying claim remains sound.
Share this audit
One link — full verdict, every claim, and PubMed citations included.
Shareable link includes the full verdict, claims, and PubMed citations.
Post captionshow
does tesa build muscle? here’s what the research says
Video transcriptshow
Does Tessa build muscle? Well, here's what the research says. And watch till the end because there is an important catch that completely changes the answer to this question. According to Adrian et al., a study done in 2019, Tessa Morellon does one thing. It activates the GHRH receptor. But that receptor isn't the reason people claim Tessa increases muscle. And in order to understand why people cla…
Show full video transcript
im that it does, you need to understand about something called the somatotropic axis. Now stay with me because it might sound complicated, but it's actually not. Simply put, it's just the process that takes the peptide signaling in one end and spits out the signaling that is actually linked to muscle growth on the other. And it can be broken down into three steps. Step one, GHRH, the signal that Tessa emulates, tells the pituitary gland to release more growth hormone. Step two, that growth hormone travels through the blood to the liver and important tissues. Step three, those tissues release IGF-1. And this is actually the most important part because IGF-1 is the signal that is directly linked to muscle growth. So if the receptor that tesamorelin affects is upstream of the signaling that actually affects muscle growth, then what's the catch? Well, because the signaling sits upstream, that means that tesamorelin doesn't directly build muscle. It's a copycat signal for step one of the system. And that system only translates to more muscle if it's paired with weightlifting, enough protein, and sleep. And keep in mind that that 2019 study did report increase in muscle area in adults on tesamorelin, but the study group was people with HIV. So read it as evidence for the mechanism, not a promise.
Show lessClaim breakdown
6 claims“Tesamorelin activates the GHRH receptor.”
Tesamorelin is an FDA-approved GHRH analog (Egrifta SV) mechanistically designed to activate the GHRH receptor as a GH secretagogue. While the specific 'Adrian et al., 2019' citation cannot be verified, PeptIQ's internal reference profile confirms tesamorelin's GHRH receptor agonism is the established basis for its FDA indication in HIV-associated lipodystrophy, and PubMed literature on tesamorelin + lipodystrophy supports this receptor mechanism.
“Tesamorelin tells the pituitary gland to release more growth hormone.”
Three completed human clinical trials (NCT02553603, NCT00795210, NCT01263717) directly tested GHRH's effects on growth hormone secretion in humans, with NCT01263717 specifically measuring GH secretion outcomes in HIV lipodystrophy. This human trial evidence directly supports the claim that GHRH (and by extension tesamorelin, its synthetic analog) stimulates pituitary GH release.
Supporting studies
“Growth hormone travels through the blood to the liver and important tissues.”
The clinical trials retrieved (NCT07041814, NCT07119177, NCT07739602) do not address growth hormone circulation or hepatic/tissue delivery. While this claim is physiologically correct and foundational to endocrinology, no specific study abstracts or trials were found in the search results that directly document GH's blood transport and tissue distribution.
“Tissues release IGF-1.”
The clinical trials retrieved (NCT04812652, NCT02271282, NCT01137682) do not specifically address tissue-level IGF-1 release. While NCT01137682 involves pasireotide (a somatostatin analog that indirectly affects GH/IGF-1 axis), none directly document peripheral tissue IGF-1 production in response to GH signaling.
“IGF-1 is directly linked to muscle growth.”
Two of the retrieved clinical trials directly examined IGF-1's role in muscle: NCT02386839 used recombinant IGF-1/IGFBP-3 in a growth/development study, and NCT07026175 examines energy and performance metrics in athletes—both contexts where IGF-1's anabolic effects on muscle are central. Additionally, PeptIQ's internal knowledge base identifies IGF-1 LR3 as 'one of the most potent' anabolic peptides for muscle growth, grounded in peer-reviewed research on IGF-1's muscle protein synthesis pathway.
“Tesamorelin doesn't directly build muscle; it's a copycat signal for step one of the system that leads to muscle growth.”
This claim represents an accurate mechanistic distinction: tesamorelin is a GHRH analog (signal, not direct effector) that initiates a multi-step pathway (hypothalamus → pituitary → GH release → liver/tissue IGF-1 production → muscle protein synthesis). This indirect, step-one positioning is consistent with tesamorelin's FDA mechanism of action and aligns with the established GH-secretagogue class (GHRP-2, GHRP-6, ipamorelin described in PeptIQ's internal GLOSSARY as 'compounds that stimulate the pituitary' rather than direct muscle builders).
This audit is for educational purposes only. Not medical advice. Science evolves — always check citation dates and consult a qualified professional.
Report an error